Last reviewed · How we verify

Staphylococcus Chronic Bronchitis — Treatment Landscape & Competitive Intelligence

Staphylococcus Chronic Bronchitis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcus Chronic Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zymar GATIFLOXACIN Allergan DNA gyrase, DNA gyrase, DNA gyrase subunit A 2003-01-01
Avelox moxifloxacin Bayer AG Fluoroquinolone antibiotic (fourth-generation) DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A 1999-12-10
Avelox Avelox Novartis Pharmaceuticals DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Staphylococcus Chronic Bronchitis
  2. Allergan · 1 drug in Staphylococcus Chronic Bronchitis
  3. Bayer AG · 1 drug in Staphylococcus Chronic Bronchitis
  4. Novartis Pharmaceuticals · 1 drug in Staphylococcus Chronic Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcus Chronic Bronchitis:

Cite this brief

Drug Landscape (2026). Staphylococcus Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcus-chronic-bronchitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing